Recon: FDA approves Lexicon’s Inpefa for heart failure; Amylyx expects negative CHMP opinion for ALS therapy
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy